Home › Kanser sa Bato (Renal Cell Carcinoma) › New York › New York City
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa New York City, NY
Isang pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa New York City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Nagre-recruitPhase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- NEO-811 NYC Site, New York
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Nagre-recruitPhase 1/2
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Nagre-recruitObservasyonal na pag-aaral
- NYU Langone Medical Center, New York
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Nagre-recruitPhase 2
- Columbia University Irving Medical Center, New York
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Nagre-recruitPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- at 1 pa
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Nagre-recruitPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- at 1 pa
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Nagre-recruitPhase 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Manhattan Eye Ear and Throat Hospital, New York
- at 2 pa
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Nagre-recruit
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nagre-recruitPhase 1
- New York Cancer & Blood Specialists, New York
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Nagre-recruitPhase 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- at 1 pa
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Nagre-recruitPhase 1
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Decision Aid (DA) for Renal Patients
Nagre-recruit
- NYU Langone Health, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Nagre-recruitPhase 1/2
- NYU Langone Health, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Nagre-recruitPhase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) sa ibang lungsod
- Houston, TX35 pag-aaral
- Nashville, TN23 pag-aaral
- Dallas, TX23 pag-aaral
- St. Louis, MO23 pag-aaral
- Los Angeles, CA20 pag-aaral
- Boston, MA16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Queens, NY15 pag-aaral
- Cleveland, OH14 pag-aaral
- Jacksonville, FL14 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.